POST Online Media Lite Edition


FDA warns drug maker about inadequate quality control

Christian Fernsby |
The U.S. Food and Drug Administration has issued a warning letter to Ningbo Huize Commodity Co., an over-the-counter drug manufacturer, for significant current good manufacturing practice violations, including data integrity issues.

Article continues below

Topics: FDA    DRUG    QUALITY   

The warning letter issued to Ningbo Huize details a failure to have adequate quality control mechanisms in place. The company provided FDA investigators multiple documents that were falsified, including the cleaning validation reports and batch production and control records for multiple drugs.

The firm also provided records showing they performed the required periodic reviews of their operation to assure quality, which they later admitted were also falsified. These CGMP violations cause all drugs manufactured by Ningbo Huize to be adulterated under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

The company has agreed to voluntarily recall drugs. The FDA requested a response from the company within 15 working days of receipt of the letter.